The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Flagged first, then by citations
2 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,002
The future of high-grade glioma: Where we are and where are we going
Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.151331 · Cited by 34
Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection
Kolb, A. L., Corridon, P. R., Zhang, S., Xu, W., Witzmann, F. A., Collett, J. A., Rhodes, G. J., Winfree, S., Bready, D., Pfeffenberger, Z. J., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060675 · Cited by 32
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Xu, H., Xia, Y., Li, C., Zhang, J., Liu, Y., Wei, Y., Qin, Z., Chen, L., Shi, Z., Quan, K., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0163-z · Cited by 32
(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
Richardson, L. G., Choi, B. D., & Curry, W. T. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.01.08 · Cited by 32
Topography of transcriptionally active chromatin in glioblastoma
Xu, L., Chen, Y., Huang, Y., Sandanaraj, E., Yu, J. S., Lin, R. Y., Dakle, P., Ke, X., Chong, Y. K., Koh, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd4676 · Cited by 35
Alhassen, S., Chen, S., Alhassen, L., Phan, A., Khoudari, M., Silva, A. D., Barhoosh, H., Wang, Z., Parrocha, C. M. T., Shapiro, E., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02255-2 · Cited by 37
Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
Cho, S. M., Esmail, A., Raza, A., Dacha, S., & Abdelrahim, M. (2022) · Cancers · doi:10.3390/cancers14112641 · Cited by 32
The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
Miller, B., Sánchez-Vega, F., & Elnitski, L. L. (2016) · Biomolecules · doi:10.3390/biom6040045 · Cited by 33
Heiland, D. H., Gaebelein, A., Börries, M., Wörner, J., Pompe, N., Franco, P., Heynckes, S., Bartholomae, M., hAilín, D. Ó., Carro, M. S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0680 · Cited by 34
Radiomics, Metabolic, and Molecular MRI for Brain Tumors
Kickingereder, P., & Andronesi, O. C. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1618600 · Cited by 31
Jeanmougin, M., Håvik, A. B., Cekaite, L., Brandal, P., Sveen, A., Meling, T. R., Ågesen, T. H., Scheie, D., Heim, S., Lothe, R. A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12668 · Cited by 31
Liu, L., Wang, G., Wang, L., Yu, C., Li, M., Song, S., Hao, L., Ma, L., & Zhang, Z. (2020) · Biology Direct · doi:10.1186/s13062-020-00264-5 · Cited by 32
Ferroptosis: iron release mechanisms in the bioenergetic process
Lee, J., & Roh, J. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10252-8 · Cited by 34
Untuning the tumor metabolic machine: HIF-α: pro- and antitumorigenic?
Young, R. M., & Simon, M. C. (2012) · Nature Medicine · doi:10.1038/nm.2865 · Cited by 31
Aury‐Landas, J., Bougeard, G., Castel, H., Hernández‐Vargas, H., Drouet, A., Latouche, J., Schouft, M., Férec, C., Leroux, D., Lasset, C., et al. (2013) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.68 · Cited by 33
Idbaïh, A., Ducray, F., Dehais, C., Courdy, C., Carpentier, C., de Bernard, S., Uro‐Coste, E., Mokhtari, K., Jouvet, A., Honnorat, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045950 · Cited by 31
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Paul, Y., Mondal, B., Patil, V. S., & Somasundaram, K. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0331-9 · Cited by 31
Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration
Cascón, A., Remacha, L., Calsina, B., & Robledo, M. (2019) · Cancers · doi:10.3390/cancers11050683 · Cited by 33
Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
Park, J., & Turcan, Ş. (2019) · Cancers · doi:10.3390/cancers11101616 · Cited by 33
Fujiwara, H., Tateishi, K., Misumi, K., Hayashi, A., Igarashi, K., Kato, H., Nakatsuka, T., Suzuki, N., Yamamoto, K., Kudo, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55211-w · Cited by 32
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
Molloy, A. R., Najac, C., Viswanath, P., Lakhani, A., Subramani, E., Batsios, G., Radoul, M., Gillespie, A. M., Pieper, R. O., & Ronen, S. M. (2020) · Theranostics · doi:10.7150/thno.47317 · Cited by 32
Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
Zhao, Y., Feng, F., Guo, Q., Wang, Y., & Zhao, R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i34.5074 · Cited by 35
Microglia-Centered Combinatorial Strategies Against Glioblastoma
Martins, T. A., Schmassmann, P., Shekarian, T., Boulay, J., Ritz, M., Zanganeh, S., Berg, J. V., & Hütter, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571951 · Cited by 32
Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity
Markouli, M., Strepkos, D., Papavassiliou, K. A., Papavassiliou, A. G., & Piperi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020540 · Cited by 33
Rohde, J. M., Surendra, K., Pragani, R., Liu, L., Fang, Y., Zhang, W., McIver, A. L., Zheng, H., Liu, Q., Davis, M. I., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00019 · Cited by 31
Identification of the Prognostic Signatures of Glioma With Different PTEN Status
Zhang, P., Meng, X., Liu, L., Li, S., Li, Y., Ali, S., Li, S., Xiong, J., Liu, X., Li, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633357 · Cited by 32
Jo, J., Díaz, M., Horbinski, C., Mackman, N., Bagley, S. J., Broekman, M., Rak, J. W., Perry, J., Pabinger, I., Key, N. S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad059 · Cited by 32
Odia, Y., Orr, B. A., Bell, W. R., Eberhart, C. G., & Rodríguez, F. J. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1221-4 · Cited by 29
Phage display discovery of novel molecular targets in glioblastoma-initiating cells
Liu, J. K., Lubelski, D., Schonberg, D. L., Wu, Q., Hale, J. S., Flavahan, W. A., Mulkearns-Hubert, E. E., Man, J., Hjelmeland, A. B., Yu, J. J., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.65 · Cited by 31
Low-grade and anaplastic oligodendroglioma
van den Bent, M. J., Bromberg, J. E. C., & Buckner, J. C. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00022-0 · Cited by 32
de Menezes, W. P., Silva, V. A. O., Gomes, I. N. F., Rosa, M. N., Spina, M. L., Carloni, A. C., Alves, A. L. V., Melendez, M. E., de Almeida, G. C., da Silva, L. S., et al. (2020) · Cells · doi:10.3390/cells9020492 · Cited by 31
Bai, X., Zhang, H., Zhou, Y., Nagaoka, K., Meng, J., Ji, C., Liu, D., Dong, X., Cao, K. Y., Mulla, J., et al. (2020) · Hepatology · doi:10.1002/hep.31486 · Cited by 31
Epigenetic plasticity, selection, and tumorigenesis
Flavahan, W. A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191215 · Cited by 31
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31
Polívka, J., Polívka, J., Rohan, V., Pešta, M., Repik, T., Pitule, P., & Topolčan, O. (2014) · BioMed Research International · doi:10.1155/2014/735659 · Cited by 31
Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin, Z., MacFadden, D. R., Alzahrani, A., Atenafu, E. G., Miller, B. A., Sahgal, A., Ménard, C. M., Laperrière, N., & Mason, W. P. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1230-3 · Cited by 30
Huse, J. T., Wallace, M., Aldape, K., Berger, M. S., Bettegowda, C., Brat, D. J., Cahill, D. P., Cloughesy, T. F., Haas-Kogan, D. A., Marra, M. A., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not229 · Cited by 31
Self-citationGenetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Testa, U., Castelli, G., & Pelosi, E. (2018) · Medical Sciences · doi:10.3390/medsci6040085 · Cited by 33
Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi, C., Roessler, S. K., Kruk, B., Lammert, F., Krawczyk, M. J., & Andersen, J. B. (2019) · Liver International · doi:10.1111/liv.14085 · Cited by 31
The CIMP-high phenotype is associated with energy metabolism alterations in colon adenocarcinoma
Fedorova, M., Krasnov, G. S., Lukyanova, E., Zaretsky, A. R., Dmitriev, A. A., Melnikova, N. V., Moskalev, A., Kharitonov, S., Pudova, E. A., Guvatova, Z. G., et al. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0771-5 · Cited by 31
5-Azacitidine in patients with IDH1/2-mutant recurrent glioma
Federici, L., Capelle, L., Annereau, M., Bielle, F., Willekens, C., Dehais, C., Laigle–Donadey, F., Hoang‐Xuan, K., Delattre, J., Idbaïh, A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa074 · Cited by 30
Chaudhary, R., Morris, R. J., & Steinson, E. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577633 · Cited by 31
2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies
Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 35
Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment
Maekawa, T., Miyake, T., Tani, M., & Üemoto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981547 · Cited by 36
Recent advances in understanding DNA methylation of prostate cancer
Shin, H. J., Hua, J. T., & Li, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1182727 · Cited by 32
Regulatory Roles of Metabolites in Cell Signaling Networks
Li, F., Xu, W., & Zhao, S. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2013.05.002 · Cited by 30
Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
Conroy, S., Kruyt, F. A. E., Joseph, J. V., Balasubramaniyan, V., Bhat, K., Wagemakers, M., Enting, R. H., Walenkamp, A., & den Dunnen, W. F. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115687 · Cited by 32
Li, S. C., Vu, L. T., Ho, H. W., Yin, H. Z., Keschrumrus, V., Lü, Q., Wang, J., Zhang, H., Ma, Z., Stover, A. E., et al. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-41 · Cited by 30
Extraordinary Cancer Epigenomics: Thinking Outside the Classical Coding and Promoter Box
Murtha, M. J., & Esteller, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.004 · Cited by 30
The Power Behind the Throne: Senescence and the Hallmarks of Cancer
Hoare, M., & Narita, M. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050352 · Cited by 33
Hopp, L., Loeffler‐Wirth, H., Galle, J., & Binder, H. (2018) · Epigenomics · doi:10.2217/epi-2017-0140 · Cited by 30
Investigation of cytotoxic, genotoxic, and apoptotic effects of curcumin on glioma cells
Seyithanoğlu, M. H., Abdallah, A., Kitiş, S., Güler, E. M., Koçyiğit, A., Dündar, T. T., & Papaker, M. G. (2019) · Cellular and Molecular Biology · doi:10.14715/cmb/2019.65.3.15 · Cited by 30
Onciul, R., Brehar, F.-M., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Dumitrascu, D.-I., Șerban, M., & Ciurea, A. V. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46030153 · Cited by 30
Contemporary murine models in preclinical astrocytoma drug development
McNeill, R. S., Vitucci, M., Wu, J., & Miller, C. R. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou288 · Cited by 31
Enigmas of IDH mutations in hematology/oncology
Heuser, M., Cruz, M. M. A., Goparaju, R., & Chaturvedi, A. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.005 · Cited by 28
Molecular and genetic pathways in gliomas: the future of personalized therapeutics
Grant, R., Kolb, L. E., & Moliterno, J. A. (2014) · CNS Oncology · doi:10.2217/cns.14.7 · Cited by 29
Kamdar, S. N., Ho, L., Kron, K. J., Isserlin, R., van der Kwast, T., Zlotta, A. R., Fleshner, N. E., Bader, G. D., & Bapat, B. V. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0195-4 · Cited by 27
Further understanding of the pathology of glioma: implications for the clinic
Camelo-Piragua, S. I., & Kesari, S. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1194755 · Cited by 29
IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53
Jiang, B., Zhao, W., Shi, M., Zhang, J., Chen, A., Ma, H., Suleman, M., Lin, F., Zhou, L., Wang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001385 · Cited by 29
Larion, M., Dowdy, T., Ruiz‐Rodado, V., Meyer, M. W., Song, H., Zhang, W., Davis, D. L., Gilbert, M. R., & Lita, A. (2018) · Biosensors · doi:10.3390/bios9010005 · Cited by 29
Yang, R., Zhao, Y., Gu, Y., Yang, Y., Gao, X., Yuan, Y., Xiao, L., Zhang, J., Sun, C., Yang, H. K., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01439-0 · Cited by 29
Polycomb repressive complex 2 in the driver’s seat of childhood and young adult brain tumours
Krug, B., Harutyunyan, A. S., Deshmukh, S., & Jabado, N. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.05.006 · Cited by 29
Oligodendroglioma: A Review of Management and Pathways
Zerdan, M. B., & Assi, H. I. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.722396 · Cited by 30
CpG Island Methylator Phenotype—A Hope for the Future or a Road to Nowhere?
Karpiński, P., & Sasiadek, M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020830 · Cited by 30
Raviram, R., Raman, A., Preißl, S., Ning, J., Wu, S., Koga, T., Zhang, K., Brennan, C., Zhu, C., Luebeck, J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210991120 · Cited by 27
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1295 · Cited by 31
Cao, Y. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0406-y · Cited by 31
Purkait, S., Sharma, V., Kumar, A., Pathak, P., Mallick, S., Jha, P., Sharma, M. C., Suri, V. S., Julka, P. K., Suri, A., et al. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.02.002 · Cited by 29
An Update on the Epigenetics of Glioblastomas
Ferreira, W. A. S., Pinheiro, D. D. R., da Costa, C. A., Rodrigues-Antunes, S., Araújo, M. D., Barros, M. B. L., Teixeira, A. C. D. S., Faro, T. A. S., Burbano, R. M. R., de Oliveira, E. H. C., et al. (2016) · Epigenomics · doi:10.2217/epi-2016-0040 · Cited by 29
Current management of low-grade gliomas
Hottinger, A. F., Hegi, M. E., & Baumert, B. G. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000390 · Cited by 28
CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
Deluche, É., Bessette, B., Durand, S., Caire, F., Rigau, V., Robert, S., Chaunavel, A., Forestier, L., Labrousse, F., Jauberteau, M., et al. (2019) · Cancers · doi:10.3390/cancers11040544 · Cited by 29
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics
Janin, M., Dávalos, V., & Esteller, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10120-3 · Cited by 30
Richardson, T. E., Walker, J. M., Hambardzumyan, D., Brem, S. S., Hatanpaa, K. J., Viapiano, M. S., Pai, B., Umphlett, M., Becher, O. J., Snuderl, M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02761-7 · Cited by 28
Lewandowska, M. A., Furtak, J., Szylberg, T., Roszkowski, K., Windorbska, W., Rytlewska, J., & Jóźwicki, W. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0050-7 · Cited by 28
Long non-coding RNA in glioma: novel genetic players in temozolomide resistance
Roh, J., Im, M., Kang, J., Youn, B., & Kim, W. (2023) · Animal Cells and Systems · doi:10.1080/19768354.2023.2175497 · Cited by 28
p53-independent tumor suppression by cell-cycle arrest via CREB/ATF transcription factor OASIS
Saito, A., Kamikawa, Y. F., Ito, T., Matsuhisa, K., Kaneko, M., Okamoto, T., Yoshimaru, T., Matsushita, Y., Katagiri, T., & Imaizumi, K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112479 · Cited by 28
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies
Toader, C., Eva, L., Costea, D., Corlatescu, A.-D., Covache-Busuioc, R.-A., Bratu, B.-G., Glavan, L.-A., Costin, H. P., Popa, A. A., & Ciurea, A. V. (2023) · Brain Sciences · doi:10.3390/brainsci13121700 · Cited by 31
The CpG Island Methylator Phenotype in Breast Cancer is Associated with the Lobular Subtype
Roessler, J., Ammerpohl, O., Gutwein, J., Steinemann, D., Schlegelberger, B., Weyer, V., Sariyar, M., Geffers, R., Arnold, N., Schmutzler, R. K., et al. (2014) · Epigenomics · doi:10.2217/epi.14.74 · Cited by 28
Alonso, S., González, B., Ruiz‐Larroya, T., Domínguez, M. D., Kato, T., Matsunaga, A., Suzuki, K., Strongin, A. Y., Gimenez‐Bonafé, P., & Perucho, M. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0158-1 · Cited by 28
Pisanic, T. R., Athamanolap, P., & Wang, T. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.030 · Cited by 27
c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas
Heiland, D. H., Ferrarese, R., Claus, R., Dai, F., Masilamani, A. P., Kling, E., Weyerbrock, A., Kling, T., Nelander, S., & Carro, M. S. (2016) · Oncotarget · doi:10.18632/oncotarget.14330 · Cited by 28
Youn, A., Kim, K. I., Rabadán, R., Tycko, B., Shen, Y., & Wang, S. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0425-z · Cited by 27
In Situ Transcriptome Accessibility Sequencing (INSTA-seq)Preprint
Fürth, D., Hatini, V., & Lee, J. H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/722819 · Cited by 28
A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma
Rolfe, N. W., Dadario, N. B., Canoll, P., & Bruce, J. N. (2024) · Pharmaceuticals · doi:10.3390/ph17080973 · Cited by 27
Developing epigenetic diagnostics and therapeutics for brain disorders
Qureshi, I., & Mehler, M. F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.003 · Cited by 30
Molecular pathology of bone tumours: diagnostic implications
Puls, F., Niblett, A., & Mangham, D. C. (2013) · Histopathology · doi:10.1111/his.12275 · Cited by 27
Garcia-Fabiani, M. B., Haase, S., Comba, A., Carney, S. V., McClellan, B. L., Banerjee, K., Alghamri, M. S., Faisal, S. M., Kadiyala, P., Núñez, F. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631037 · Cited by 30
Pappula, A. L., Rasheed, S., Mirzaei, G., Petreaca, R. C., & Bouley, R. A. (2021) · Cancers · doi:10.3390/cancers13174299 · Cited by 27
A Comprehensive Review of Genomics and Noncoding RNA in Gliomas
Hassan, A. M., Mosley, J. C., Singh, S. K., & Zinn, P. O. (2017) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000111 · Cited by 28
Tong, L., Li, J., Choi, J. H., Pant, A., Xia, Y., Jackson, C. M., Liu, P., Li, Y., Boussouf, E., Lim, M. K., et al. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0140-8 · Cited by 27
McGovern, A. P., Powell, B. E., & Chevassut, T. J. T. (2012) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.06.018 · Cited by 27
Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas
Olar, A., & Aldape, K. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0210-8 · Cited by 26
The integrative metabolomic-transcriptomic landscape of glioblastome multiforme
Heiland, D. H., Wörner, J., Haaker, J. G., Delev, D., Pompe, N., Mercas, B., Franco, P., Gaebelein, A., Heynckes, S., Pfeifer, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16544 · Cited by 27
mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma
Liu, Y., Lu, Y., Li, A., Celiku, O., Han, S., Qian, M., & Yang, C. (2020) · Cancers · doi:10.3390/cancers12040787 · Cited by 26
Intermediary metabolism: An intricate network at the crossroads of cell fate and function
Ferreira, L. M. R., Li, A. M., Serafim, T. L., Sobral, M. C. M., Alpoim, M. C., & Urbano, A. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165887 · Cited by 27
Cejalvo, T., Gargini, R., Segura‐Collar, B., Mata-Martínez, P., Herránz, B., Cantero, D., Ruano, Y., García‐Pérez, D., Pérez‐Núñez, Á., Ramos, A., et al. (2020) · Cancers · doi:10.3390/cancers12113230 · Cited by 26
Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers
Sharma, A., Liu, H., Herwig‐Carl, M. C., Dakal, T. C., & Schmidt‐Wolf, I. G. H. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1872593 · Cited by 26
Verheul, C., Ntafoulis, I., Kers, T. V., Hoogstrate, Y., Mastroberardino, P. G., Barnhoorn, S., Payán‐Gómez, C., Yen, R. T. C., Struys, E. A., Koolen, S. L. W., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab103 · Cited by 26
ARID1A loss-of-function induces CpG island methylator phenotype
Yamada, H., Takeshima, H., Fujiki, R., Yamashita, S., Sekine, S., Ando, T., Hattori, N., Okabe, A., Yoshikawa, T., Obama, K., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215587 · Cited by 26
Venous thromboembolic events in glioblastoma patients: An epidemiological study
Eisele, A., Seystahl, K., Rushing, E. J., Roth, P., Rhun, É. L., Weller, M., & Gramatzki, D. (2022) · European Journal of Neurology · doi:10.1111/ene.15404 · Cited by 26
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
